Literature DB >> 9431921

Evaluation of a new method for rapid drug susceptibility testing of Mycobacterium avium complex isolates by using the mycobacteria growth indicator tube.

C Piersimoni1, D Nista, S Bornigia, G De Sio.   

Abstract

The reliability of the Mycobacteria Growth Indicator Tube (MGIT [BBL]) for rapid drug susceptibility testing of Mycobacterium avium complex (MAC) isolates was evaluated. MICs of amikacin, clarithromycin, clofazimine, ethambutol, and rifabutin were determined by the MGIT system for 16 MAC strains. The results were compared with those obtained by the BACTEC broth macrodilution method. The turnaround times were 6 to 8 days (median, 7 days) for the MGIT and 5 to 7 days (median, 6 days) for the BACTEC system. Agreements with BACTEC system-determined MICs, within +/-1 log2 dilution, were 100, 100, 88, 63, and 44% for amikacin, clofazimine, rifabutin, clarithromycin, and ethambutol, respectively. Within +/-2 log2 dilutions, agreement with BACTEC system-determined MICs increased to 100% for all the tested drugs. In addition, if MGIT-determined MICs were evaluated according to the thresholds adopted for the interpretation of BACTEC system-determined ones, ethambutol was the only drug for which susceptible strains were frequently misclassified as resistant. It is concluded that the MGIT system is a promising, nonradiometric alternative to the BACTEC method for rapid susceptibility testing of MAC isolates; however, additional studies are required to confirm our results and to determine the optimal criteria for the interpretation of ethambutol MICs.

Entities:  

Mesh:

Year:  1998        PMID: 9431921      PMCID: PMC124808     

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  7 in total

Review 1.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

2.  Treatment of Mycobacterium avium complex infection: do the results of in vitro susceptibility tests predict therapeutic outcome in humans?

Authors:  J P Sison; Y Yao; C A Kemper; J R Hamilton; E Brummer; D A Stevens; S C Deresinski
Journal:  J Infect Dis       Date:  1996-03       Impact factor: 5.226

Review 3.  Mycobacterium avium complex infection. Pharmacokinetic and pharmacodynamic considerations that may improve clinical outcomes.

Authors:  C A Peloquin
Journal:  Clin Pharmacokinet       Date:  1997-02       Impact factor: 6.447

4.  A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group.

Authors:  S D Shafran; J Singer; D P Zarowny; P Phillips; I Salit; S L Walmsley; I W Fong; M J Gill; A R Rachlis; R G Lalonde; M M Fanning; C M Tsoukas
Journal:  N Engl J Med       Date:  1996-08-08       Impact factor: 91.245

5.  Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex.

Authors:  H Masur
Journal:  N Engl J Med       Date:  1993-09-16       Impact factor: 91.245

6.  Evaluation of mycobacteria growth indicator tubes for susceptibility testing of Mycobacterium tuberculosis to isoniazid and rifampin.

Authors:  B S Reisner; A M Gatson; G L Woods
Journal:  Diagn Microbiol Infect Dis       Date:  1995-08       Impact factor: 2.803

7.  Testing of susceptibility of Mycobacterium tuberculosis to isoniazid and rifampin by mycobacterium growth indicator tube method.

Authors:  S B Walters; B A Hanna
Journal:  J Clin Microbiol       Date:  1996-06       Impact factor: 5.948

  7 in total
  2 in total

1.  Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.

Authors:  Sung Jae Shin; Michael T Collins
Journal:  Antimicrob Agents Chemother       Date:  2007-12-10       Impact factor: 5.191

2.  Atypical mycobacterial infections.

Authors:  S Venkatesh Karthik; Kalyani V Mulay
Journal:  J R Soc Med       Date:  2003-05       Impact factor: 18.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.